Citation
Knapp, Martin, et al. "Cost-effectiveness of Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (the DOMINO-AD Trial)." International Journal of Geriatric Psychiatry, vol. 32, no. 12, 2017, pp. 1205-1216.
Knapp M, King D, Romeo R, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017;32(12):1205-1216.
Knapp, M., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., Burns, A., Dening, T., Findlay, D., Holmes, C., Johnson, T., Jones, R., Katona, C., Lindesay, J., Macharouthu, A., ... Howard, R. (2017). Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). International Journal of Geriatric Psychiatry, 32(12), 1205-1216. https://doi.org/10.1002/gps.4583
Knapp M, et al. Cost-effectiveness of Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (the DOMINO-AD Trial). Int J Geriatr Psychiatry. 2017;32(12):1205-1216. PubMed PMID: 27739182.
TY - JOUR
T1 - Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
AU - Knapp,Martin,
AU - King,Derek,
AU - Romeo,Renée,
AU - Adams,Jessica,
AU - Baldwin,Ashley,
AU - Ballard,Clive,
AU - Banerjee,Sube,
AU - Barber,Robert,
AU - Bentham,Peter,
AU - Brown,Richard G,
AU - Burns,Alistair,
AU - Dening,Tom,
AU - Findlay,David,
AU - Holmes,Clive,
AU - Johnson,Tony,
AU - Jones,Robert,
AU - Katona,Cornelius,
AU - Lindesay,James,
AU - Macharouthu,Ajay,
AU - McKeith,Ian,
AU - McShane,Rupert,
AU - O'Brien,John T,
AU - Phillips,Patrick P J,
AU - Sheehan,Bart,
AU - Howard,Robert,
Y1 - 2016/10/13/
PY - 2016/05/19/received
PY - 2016/08/25/revised
PY - 2016/08/25/accepted
PY - 2016/10/16/pubmed
PY - 2018/6/21/medline
PY - 2016/10/15/entrez
KW - Alzheimer's disease
KW - cost-effectiveness
KW - donepezil
KW - memantine
SP - 1205
EP - 1216
JF - International journal of geriatric psychiatry
JO - Int J Geriatr Psychiatry
VL - 32
IS - 12
N2 - OBJECTIVE: Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. METHODS: Cost-effectiveness analysis was based on a 52-week, multicentre, double-blind, placebo-controlled, factorial clinical trial. A total of 295 community-dwelling patients with moderate/severe Alzheimer's disease, already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii) discontinue donepezil and start memantine; or (iv) continue donepezil and start memantine. RESULTS: Continuing donepezil for 52 weeks was more cost-effective than discontinuation, considering cognition, activities of daily living and health-related quality of life. Starting memantine was more cost-effective than donepezil discontinuation. Donepezil-memantine combined is not more cost-effective than donepezil alone. CONCLUSIONS: Robust evidence is now available to inform clinical decisions and commissioning strategies so as to improve patients' lives whilst making efficient use of available resources. Clinical guidelines for treating moderate/severe Alzheimer's disease, such as those issued by NICE in England and Wales, should be revisited. © 2016 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
SN - 1099-1166
UR - https://www.unboundmedicine.com/medline/citation/27739182/Cost_effectiveness_of_donepezil_and_memantine_in_moderate_to_severe_Alzheimer's_disease__the_DOMINO_AD_trial__
DB - PRIME
DP - Unbound Medicine
ER -